Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines

Executive Summary

Plans to have candidate vaccines ready for testing against infectious diseases during an evolving epidemic have taken a step forward with the announcement of a partnership between CEPI, the global fund supported by governments and philanthropists, and the vaccine-focused European biotech, Themis Bioscience.

Advertisement

Related Content

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
Bharat Enters Chikungunya Fray As Vaccine Moves Into Trials
CEPI Global Vaccines Launch May Augur Creation Of Credible Davos Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel